WHOLE SHINE MEDICAL 2026Q3: Revenue RMB 206 Million, Down 3.23% YoY; Net Profit Attributable to Shareholders of the Parent Company Turns Positive YoY

Source: Haochen Medical 2026 Third Quarter Report

Q3 single-quarter net profit attributable to shareholders of the parent company was 1.7893 million yuan, turning from loss to profit / Net loss attributable to shareholders of the parent company for the first three quarters was 12.2366 million yuan / Operating Cash Flow (OCF) for the first three quarters was 45.5987 million yuan

DentalGoodNews｜On October 30, 2026, WHOLE SHINE MEDICAL TECHNOLOGY CO.,LTD. (hereinafter referred to as "WHOLE SHINE MEDICAL") disclosed its unaudited third-quarter report for 2026. Single-quarter revenue for Q3 was 206 million yuan, down 3.23% year on year; net profit attributable to shareholders of the parent company was 1.7893 million yuan, up 167.30% year on year; according to prior DGN reporting, the single-quarter net profit attributable to shareholders of the parent company in the same period last year was a loss of 2.66 million yuan.

Cumulative revenue for the first three quarters was 520 million yuan, down 1.23% year on year; net loss attributable to shareholders of the parent company was 12.2366 million yuan, compared with a loss of 26.4098 million yuan in the same period last year, a year-on-year reduction in loss of 53.67%. On a consolidated basis, net profit for the first three quarters was 9.3232 million yuan, compared with a loss of 31.0252 million yuan in the same period last year; of which profit or loss attributable to minority shareholders was 21.5598 million yuan, compared with -4.6154 million yuan in the same period last year.

Source: Haochen Medical 2026 Third Quarter Report

In terms of costs and expenses, Operating cost for the first three quarters was 241 million yuan, down 12.54% year on year, accounting for 46.29% of Operating revenue, compared with 52.28% in the same period last year. Selling expenses were 124 million yuan, down 5.94% year on year; administrative expenses were 107 million yuan, up 0.98% year on year; R&D expenses were 9.2361 million yuan, down 20.70% year on year; financial expenses were 27.7763 million yuan, down 10.83% year on year, of which interest expenses were 27.3741 million yuan, compared with 30.2823 million yuan in the same period last year.

Source: Haochen Medical 2026 Third Quarter Report

In terms of cash flow, net cash flow from operating activities for the first three quarters was 45.5987 million yuan, compared with -10.1462 million yuan in the same period last year, turning from negative to positive. Net cash flow from investing activities was -1.7729 million yuan; net cash flow from financing activities was -21.6410 million yuan, of which cash paid for distribution of dividends, profits or interest payments was 24.3255 million yuan, compared with 13.5656 million yuan in the same period last year. The balance of cash and cash equivalents at the end of the period was 144 million yuan, compared with 110 million yuan at the end of the same period last year.

In terms of assets and liabilities, as of September 30, 2026, total assets were 1.349 billion yuan, down 0.70% from the end of the previous year; equity attributable to owners of the parent company was 263 million yuan, down 2.96% from the end of the previous year.

Due to the case involving Jinhaitang Asset Management Co., Ltd., the Shanghai Financial Court held an auction from August 24 to 27, 2026, of the company's 227 million yuan capital contribution equity in Fushun Bank (shareholding ratio 6.68%), which resulted in a failed auction; the creditor's rights in the case were subsequently transferred to Fushun Urban Construction Investment Co., Ltd., which was ruled to be changed to the applicant for execution. On October 26, the company learned upon inquiry that the Liaoning Financial Regulatory Bureau had approved its succession to the aforementioned shares (Liao Jin Fu [2026] No. 242). The company stated that this approval is a pre-approval procedure, the creditor's rights transfer agreement has not yet been fully performed, and the equity transfer and change registration have not been completed, so it does not constitute completion of a change in ownership.

In terms of judicial freezing, the equity of Zhiyu Medical Investment Co., Ltd. was frozen by the Beijing First Intermediate People's Court (equity amount 50 million yuan), and the real estate and some vehicles of Yongda Electric were seized, with 4.1486 million yuan having been judicially transferred; on September 29, 2026, the court's "Notice of Execution" was served on the company, and the case resumed execution. The company stated that it cannot rule out the risk of further freezing or disposal of bank accounts or assets. In addition, the 51% equity of Delun Medical held by Zhiyu Medical (corresponding to a capital contribution of 26.52 million yuan) was frozen by the Jilin City Chuanying District People's Court; the court dismissed the litigation claims of Zhejiang Zhebai Xiannvhu Enterprise Management Partnership (Limited Partnership) in the first instance, and the plaintiff has appealed, with the second-instance judgment not yet rendered.

According to a separate company announcement, director Huang Zhaobiao resigned from his position as a director of the fifth board of directors for personal reasons, with the resignation report served on the board on October 28, 2026. He does not hold shares in the company, and the resignation will not cause the number of board members to fall below the statutory minimum.